Received May 22, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | D243K | — |
Administration of only the adjuvant component; Administration of only the adjuvant component; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 51-year-old female patient who received Herpes zoster (Shingrix) (batch number D243K, expiry date 17-MAY-2026) for prophylaxis. On 05-MAY-2026, the patient received Shingrix. On 05-MAY-2026, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: Administration of only the adjuvant component) and inappropriate dose of vaccine administered (Verbatim: Administration of only the adjuvant component). The outcome of the inappropriate preparation of medication was unknown and the outcome of the inappropriate dose of vaccine administered was not applicable. Additional Information: GSK Receipt Date: 18-MAY-2026 and 19-MAY-2026 A patient received a Shingrix vaccine but only the liquid was administered without reconstituting it with the powder. It was confirmed during the call that the liquid was the adjuvant component of the vaccine. No further details were provided. Vaccine coordinator called back today to state that the situation was that they used the Shingrix powder and used sterile water diluent to mix it instead of how it was reported yesterday.